$3.67 Million in Sales Expected for Epizyme, Inc. (EPZM) This Quarter
Equities research analysts expect Epizyme, Inc. (NASDAQ:EPZM) to report sales of $3.67 million for the current quarter, according to Zacks. Three analysts have issued estimates for Epizyme’s earnings, with estimates ranging from $500,000.00 to $10.00 million. Epizyme reported sales of $6.58 million during the same quarter last year, which would suggest a negative year over year growth rate of 44.2%. The company is expected to issue its next quarterly earnings report before the market opens on Wednesday, November 1st.
According to Zacks, analysts expect that Epizyme will report full-year sales of $3.67 million for the current year, with estimates ranging from $10.00 million to $11.00 million. For the next fiscal year, analysts expect that the firm will post sales of $13.09 million per share, with estimates ranging from $1.36 million to $53.60 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Epizyme.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.08. The firm had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.95 million. During the same quarter last year, the firm earned ($0.49) EPS. The company’s revenue was up 2027.7% on a year-over-year basis.
EPZM has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Wednesday, July 12th. BidaskClub lowered shares of Epizyme from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Royal Bank Of Canada set a $20.00 price objective on shares of Epizyme and gave the company a “buy” rating in a research note on Saturday, August 5th. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research note on Monday, August 7th. Finally, Leerink Swann reiterated an “outperform” rating and set a $28.00 price objective (down previously from $31.00) on shares of Epizyme in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $23.78.
Epizyme (NASDAQ:EPZM) opened at 16.80 on Tuesday. The firm’s market cap is $982.23 million. Epizyme has a 12-month low of $8.50 and a 12-month high of $20.45. The firm’s 50-day moving average is $17.59 and its 200 day moving average is $15.56.
In other news, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $15.68, for a total transaction of $235,200.00. Following the completion of the sale, the insider now owns 22,228 shares of the company’s stock, valued at $348,535.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David M. Mott purchased 200,000 shares of the firm’s stock in a transaction dated Monday, September 18th. The shares were bought at an average cost of $15.25 per share, with a total value of $3,050,000.00. Following the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $91,500. The disclosure for this purchase can be found here. Insiders have sold 45,000 shares of company stock valued at $733,950 in the last three months. Corporate insiders own 25.20% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc grew its position in shares of Epizyme by 8.9% during the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares in the last quarter. UBS Asset Management Americas Inc. acquired a new stake in shares of Epizyme during the first quarter worth approximately $175,000. Fox Run Management L.L.C. acquired a new stake in shares of Epizyme during the third quarter worth approximately $223,000. BB&T Securities LLC acquired a new stake in shares of Epizyme during the second quarter worth approximately $181,000. Finally, Trexquant Investment LP acquired a new stake in shares of Epizyme during the second quarter worth approximately $184,000. 72.20% of the stock is owned by institutional investors and hedge funds.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.